Niagen Bioscience (NAGE) Cost of Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has reported Cost of Revenue for 17 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 364.0% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $30.0 million (up 20.45% YoY), while the FY2025 annual figure was $11.6 million, down 69.5% from the prior year.
• Cost of Revenue grew to $11.5 million in Q1 2026 per NAGE's latest filing, from $3.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $12.1 million in Q3 2025 and bottomed at $2.1 million in Q2 2024.
• Historically, Cost of Revenue has averaged $7.4 million across 5 years, with a median of $8.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cost of Revenue slumped 73.37% — and 2026, when it jumped 364.0%.
• Niagen Bioscience's Cost of Revenue stood at $9.0 million in 2022, then slipped by 8.03% to $8.3 million in 2023, then jumped by 32.32% to $10.9 million in 2024, then sank by 64.87% to $3.8 million in 2025, then soared by 199.51% to $11.5 million in 2026.
• Business Quant data shows NAGE's Cost of Revenue at $11.5 million in Q1 2026, $3.8 million in Q4 2025, and $12.1 million in Q3 2025.